About this resource
Publication date:
Publication type:
Report
Audience:
General public
Language:
English
Australian Government Department of Health, Disability and Ageing
Life Saving Drugs Program (LSDP) – Olipudase alfa (Xenpozyme®) outcome statement
Summary of the consideration of the application from Sanofi Australia and New Zealand for the inclusion of olipudase alfa (Xenpozyme®) on the LSDP for the treatment of acid sphingomyelinase deficiency (ASMD) types A/B and B.